2617.HK
TRANSTHERA-B
HK$35.02
-3.74%
2026-05-29
About TRANSTHERA-B
TransThera Sciences (Nanjing), Inc., clinical stage pharmaceutical company company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a multi-kinase inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. The company has a collaboration with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors for multiple disease; and Akeso, Inc. for the treatment of hepatocellular carcinoma. TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.
Key Fundamentals
EPS (TTM)
HK$-0.88
ROE
-62.9%
Profit Margin
0.0%
Debt/Equity
0.40
Price/Book
28.89
Market Cap
HK$14.29B
Avg Volume (10D)
1.8M
Recent Breakout Signals
No recent breakout signals detected for 2617.HK.
Recent Price Range (60 Days)
60D High
HK$94.45
60D Low
HK$34.56
Avg Volume
2.6M
Latest Close
HK$35.02
Get breakout alerts for 2617.HK
Sign up for Breakout Scanner to receive daily notifications when 2617.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
TRANSTHERA-B (2617.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 2617.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 2617.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.